Rocket Pharmaceuticals outlines FDA-aligned pivotal Phase 2 path for gene therapy RP-A501 in Danon disease

What's the deal? Rocket Pharmaceuticals shared updated clinical findings and a defined regulatory path for RP-A501, its investigational gene therapy for Danon disease, after an investor webinar on 6 October 2026. Danon disease is a rare inherited disorder that causes progressive heart failure, typically in young men. The company confirmed that the FDA-aligned pivotal Phase 2 trial will evaluate 12 male patients at a recalibrated dose, with the first three already treated under a revised protocol counting toward that total.

Why it matters: RP-A501 is delivered as a single intravenous infusion and is designed to restore a missing heart protein (LAMP2) by delivering a working copy of the gene, with the goal of stabilising or improving cardiac function. Long-term follow-up from the earlier Phase 1 study showed that after roughly three to seven years, five of six patients had heart-mass measurements below baseline, and all six had sustained improvements in cardiac biomarkers and quality of life. The first three patients treated at the recalibrated dose showed no signs of the blood-clotting or fluid-leak complications seen with the original higher dose. Trial success requires at least seven of 12 patients to meet both response criteria at 12 months. Rocket expects to complete dosing by mid-2027 and to report topline results around mid-2028, aiming for a potential accelerated approval.

Read more: Rocket Pharmaceuticals via Business Wire, 7 October 2026